Mr. Speaker, with regard to part (a) to date, the Government of Canada has signed nine agreements with vaccine suppliers, which include the following: i) an advance purchase agreement, APA, with Pfizer-BioNTech, which will supply up to 76 million doses of its mRNA-based vaccine, BNY162. The agreement in principle was signed on August 1, 2020; ii) an APA with AstraZeneca, which will supply 20 million doses of its viral vector vaccine candidate, AZD1222. The agreement in principle was signed on September 24, 2020; iii) an APA with Sanofi and GlaxoSmithKline, which will supply up to 72 million of doses of their protein subunit vaccine candidate and AS03 adjuvant. The agreements were signed on September 11, 2020, and September 18, 2020, respectively; iv) an APA with AstraZeneca for the supply of Canada’s COVAX allocation of the AstraZeneca vaccine. This APA was signed on March 2, 2021; v) an APA with Medicago, which will supply up to 76 million doses of its virus-like particle vaccine candidate. The agreement in principle was signed on October 22, 2020; vi) a contract with Verity Pharmaceuticals Inc. and Serum Institute of India, which will supply up to two million doses of its viral vector vaccine candidate, COVISHIELD. The contract was signed February 24, 2021; vii) an APA with Moderna, which will supply 44 million doses of its mRNA-based vaccine, mRNA-1273. The agreement was signed on July 24, 2020; viii) an APA with Johnson & Johnson, which will supply up to 38 million doses of its viral vector vaccine candidate, Ad26.COV2.S. The agreement in principle was signed on August 21, 2020; and ix) an APA with Novavax, which will supply up to 76 million doses of its protein subunit vaccine candidate, NVX-CoV2373. The agreement in principle was signed on August 27, 2020.
With regard to parts (b), (c) and (d), PSPC cannot disclose details of specific vaccine agreements unilaterally, in order to respect confidentiality agreements with suppliers and protect our negotiating position. We continue to have discussions with suppliers about opportunities to share information publicly.